#ViiV #Pfizer #ViiVHealthcare #Shionogi #HIV #GSK #strategicpartnership #jointventure #HIVtherapies #GileadSciences #HIVtreatment #antiretroviraltherapy #longeractinginjectableregimens #HIVpreexposureprophylaxis #PrEP #preexposureprophylaxis #Apretude #cabotegravir #lenacapavir
zurl.co/khJ6D
zurl.co/khJ6D
ViiV ownership shifts as Pfizer sells its stake
Pfizer will relinquish its stake in HIV firm ViiV in a deal valued at $2.1bn that ramps up Shionogi's interest and simplifies its share structure
pharmaphorum.com
January 27, 2026 at 11:46 AM
The #GileadSciences Research Scholars Program awards provide two years of financial support to junior faculty researchers. Each award is funded depending on country and region, paid as two annual installments directly to the scholar’s institution. Learn more: researchscholars.gilead.com
Apply Now! #GileadSciences is accepting applications for their Research Scholars Program designed for emerging researchers from community health organizations in the US, applications must be submitted by March 16, 2026, at 11:59 PM PT. Learn more: researchscholars.gilead.com
January 23, 2026 at 12:47 AM
The #GileadSciences Research Scholars Program awards provide two years of financial support to junior faculty researchers. Each award is funded depending on country and region, paid as two annual installments directly to the scholar’s institution. Learn more: researchscholars.gilead.com
Apply Now! #GileadSciences is accepting applications for their Research Scholars Program designed for emerging researchers from community health organizations in the US, applications must be submitted by March 16, 2026, at 11:59 PM PT. Learn more: researchscholars.gilead.com
January 14, 2026 at 10:01 PM
Apply Now! #GileadSciences is accepting applications for their Research Scholars Program designed for emerging researchers from community health organizations in the US, applications must be submitted by March 16, 2026, at 11:59 PM PT. Learn more: researchscholars.gilead.com
#research #medchem #virology
Exploring advanced methodologies for NS5 methyltransferase targeted drug discovery (Otava, Drexler, Boura, Nencka) – Eur. J. Med. Chem.: doi.org/10.1016/j.ej...
@iocbprague.bsky.social @czechacademy.bsky.social @sciencecharles.bsky.social #gileadsciences
Exploring advanced methodologies for NS5 methyltransferase targeted drug discovery (Otava, Drexler, Boura, Nencka) – Eur. J. Med. Chem.: doi.org/10.1016/j.ej...
@iocbprague.bsky.social @czechacademy.bsky.social @sciencecharles.bsky.social #gileadsciences
January 13, 2026 at 2:01 PM
#research #medchem #virology
Exploring advanced methodologies for NS5 methyltransferase targeted drug discovery (Otava, Drexler, Boura, Nencka) – Eur. J. Med. Chem.: doi.org/10.1016/j.ej...
@iocbprague.bsky.social @czechacademy.bsky.social @sciencecharles.bsky.social #gileadsciences
Exploring advanced methodologies for NS5 methyltransferase targeted drug discovery (Otava, Drexler, Boura, Nencka) – Eur. J. Med. Chem.: doi.org/10.1016/j.ej...
@iocbprague.bsky.social @czechacademy.bsky.social @sciencecharles.bsky.social #gileadsciences
Finaliza con éxito la 8ª edición del programa Counselling: 4 médicos han recibido tutorías para mejorar la atención a pacientes con #VIH 🩺. Gracias a #GileadSciences y #MSDEspana
Programa de tutorías en VIH | Formación personalizada para médicos - ScienHub
Mejora tus habilidades en el manejo del VIH con nuestro programa de tutorías personalizadas. Aprende de expertos y adquiere mayor confianza en tu consulta médica.
f.mtr.cool
January 2, 2026 at 10:32 AM
Finaliza con éxito la 8ª edición del programa Counselling: 4 médicos han recibido tutorías para mejorar la atención a pacientes con #VIH 🩺. Gracias a #GileadSciences y #MSDEspana
🦠6 años después del inicio de la #COVID19, el Dr. JM Miró presenta su actualización:
- Evolución de variantes
- Avances en vacunas 2025–26
- Tratamientos recientes
- Hallazgos sobre #longCOVID
▶️Mírala aquí: youtu.be/Y05rs3VGbSM?...
Gracias a
@moderna_tx y @GileadSciences
- Evolución de variantes
- Avances en vacunas 2025–26
- Tratamientos recientes
- Hallazgos sobre #longCOVID
▶️Mírala aquí: youtu.be/Y05rs3VGbSM?...
Gracias a
@moderna_tx y @GileadSciences
COVID-19: 6 años más tarde. La actualización final
YouTube video by ScienHub
youtu.be
December 23, 2025 at 7:52 AM
🦠6 años después del inicio de la #COVID19, el Dr. JM Miró presenta su actualización:
- Evolución de variantes
- Avances en vacunas 2025–26
- Tratamientos recientes
- Hallazgos sobre #longCOVID
▶️Mírala aquí: youtu.be/Y05rs3VGbSM?...
Gracias a
@moderna_tx y @GileadSciences
- Evolución de variantes
- Avances en vacunas 2025–26
- Tratamientos recientes
- Hallazgos sobre #longCOVID
▶️Mírala aquí: youtu.be/Y05rs3VGbSM?...
Gracias a
@moderna_tx y @GileadSciences
▶️¡En directo! #OptimiTAR, un espacio dedicado a optimizar el #TAR en pacientes con resistencia virológica. Revisamos 4 casos clínicos. Puedes ver el directo aquí: https://f.mtr.cool/ntmevwhmsm
Gracias al apoyo de #GileadSciences
Gracias al apoyo de #GileadSciences
Welcome! You are invited to join a meeting: OptimiTAR 10/12/2025. After registering, you will receive a confirmation email about joining the meeting.
Welcome! You are invited to join a meeting: OptimiTAR 10/12/2025. After registering, you will receive a confirmation email about joining the meeting.
f.mtr.cool
December 10, 2025 at 3:28 PM
▶️¡En directo! #OptimiTAR, un espacio dedicado a optimizar el #TAR en pacientes con resistencia virológica. Revisamos 4 casos clínicos. Puedes ver el directo aquí: https://f.mtr.cool/ntmevwhmsm
Gracias al apoyo de #GileadSciences
Gracias al apoyo de #GileadSciences
#GileadSciences' #Kite unit has showcased three new #CARTtherapies at #ASH, headed by #multiplemyeloma candidate anitocabtagene autoleucel (anito-cel), which is being prepared for a filing and potential launch in 2026.
pharmaphorum.com/news/ash-gil...
pharmaphorum.com/news/ash-gil...
ASH: Gilead preps filing for anito-cel on iMMagine-1 data
Gilead's Kite unit has showcased three new CAR-T therapies at ASH, headed by multiple myeloma candidate anito-cel, which could launch next year.
pharmaphorum.com
December 8, 2025 at 5:20 PM
#GileadSciences' #Kite unit has showcased three new #CARTtherapies at #ASH, headed by #multiplemyeloma candidate anitocabtagene autoleucel (anito-cel), which is being prepared for a filing and potential launch in 2026.
pharmaphorum.com/news/ash-gil...
pharmaphorum.com/news/ash-gil...
HEALTH - It's a twice annual injectable good for long journeys and times you might not have access to a daily pill. Read more at link👇
buff.ly/5QD9iuX
#HIVTreatment #Lenacapavir #Sunlenca #Yeztugo #HIVCare #EndHIV #PublicHealthNC #HIVAware #GileadSciences #HIVPrevention #LGBTQHealth
buff.ly/5QD9iuX
#HIVTreatment #Lenacapavir #Sunlenca #Yeztugo #HIVCare #EndHIV #PublicHealthNC #HIVAware #GileadSciences #HIVPrevention #LGBTQHealth
There is an alternative to daily antiretroviral therapy - QnotesCarolinas.com
Sunlenca (Lenacapavir) offers twice-yearly HIV treatment and prevention. Learn its benefits, risks, cost, and access options in North Carolina.
qnotescarolinas.com
November 26, 2025 at 7:02 PM
HEALTH - It's a twice annual injectable good for long journeys and times you might not have access to a daily pill. Read more at link👇
buff.ly/5QD9iuX
#HIVTreatment #Lenacapavir #Sunlenca #Yeztugo #HIVCare #EndHIV #PublicHealthNC #HIVAware #GileadSciences #HIVPrevention #LGBTQHealth
buff.ly/5QD9iuX
#HIVTreatment #Lenacapavir #Sunlenca #Yeztugo #HIVCare #EndHIV #PublicHealthNC #HIVAware #GileadSciences #HIVPrevention #LGBTQHealth
The 2nd European Workshop on Breaking PrEP Barriers with #BCNCheckpoint gathered 90+ participants to advance equitable PrEP access. Thanks to all, especially #GileadSciences & #ViiVHC 📹 The workshop recording is now available: webinars.scienhub.org/courses/brea...
2nd European Workshop on Breaking PrEP Barriers | ScienHub Webinars
Since its implementation in Europe, access to pre-exposure prophylaxis (PrEP) has been marked by numerous challenges, particularly affecting the most vulnerable populations. Waiting lists, administrat...
webinars.scienhub.org
November 21, 2025 at 8:41 AM
The 2nd European Workshop on Breaking PrEP Barriers with #BCNCheckpoint gathered 90+ participants to advance equitable PrEP access. Thanks to all, especially #GileadSciences & #ViiVHC 📹 The workshop recording is now available: webinars.scienhub.org/courses/brea...
.@CNBC aired a half-hour documentary on the practice of employer health plans forcing patients to take illegally imported and unsafe medications. Thanks to @SafeMedicines & @GileadSciences for their leadership on combating counterfeit drugs. Watch here: www.youtube.com/watch?v=9iKA...
How Soaring U.S. Drug Prices Fueled What Feds Call An Illegal Import Of Medications
YouTube video by CNBC
www.youtube.com
November 14, 2025 at 9:50 PM
.@CNBC aired a half-hour documentary on the practice of employer health plans forcing patients to take illegally imported and unsafe medications. Thanks to @SafeMedicines & @GileadSciences for their leadership on combating counterfeit drugs. Watch here: www.youtube.com/watch?v=9iKA...
Next at #AgingInHIV: Pharma innovations & challenges for older #PLWHIV 💊Insights from Ana Milinkovic #ViiVHealthcare, Cristina de Álvaro #GileadSciences & Emiliano Bissio #MSD on shaping the future of HIV treatment.
November 14, 2025 at 11:12 AM
Next at #AgingInHIV: Pharma innovations & challenges for older #PLWHIV 💊Insights from Ana Milinkovic #ViiVHealthcare, Cristina de Álvaro #GileadSciences & Emiliano Bissio #MSD on shaping the future of HIV treatment.
Kudos to @GileadSciences 👏👏
Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV-1 Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-1 Trial www.gilead.com/news/news-de...
Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV-1 Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-1 Trial www.gilead.com/news/news-de...
Gilead’s Investigational Single Tablet Regimen of Bictegravir and Lenacapavir for HIV 1 Treatment Meets Primary Endpoint in Phase 3 ARTISTRY 1 Trial
Gilead’s Investigational Single Tablet Regimen of Bictegravir and Lenacapavir for HIV 1 Treatment Meets Primary Endpoint in Phase 3 ARTISTRY 1 Trial
www.gilead.com
November 13, 2025 at 8:35 PM
Kudos to @GileadSciences 👏👏
Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV-1 Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-1 Trial www.gilead.com/news/news-de...
Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV-1 Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-1 Trial www.gilead.com/news/news-de...
It's worth noting, again, that patient advocates and their valued relationships with @GileadSciences made this decision possible, not the typical pharma-bashing jargon or grandstanding by politicians seeking the next 30-second sound bite.
www.statnews.com/pharmalot/20...
www.statnews.com/pharmalot/20...
Gilead agrees not to raise prices on HIV medicines for state AIDS drug programs
After tense negotiations, Gilead Sciences has agreed not to boost prices next year for HIV medicines that are sold to state AIDS Drug Assistance Programs.
www.statnews.com
October 22, 2025 at 6:32 PM
It's worth noting, again, that patient advocates and their valued relationships with @GileadSciences made this decision possible, not the typical pharma-bashing jargon or grandstanding by politicians seeking the next 30-second sound bite.
www.statnews.com/pharmalot/20...
www.statnews.com/pharmalot/20...
Kudos to @GileadSciences for doing the right thing. Our statement is forthcoming...
👇
Gilead agrees not to raise prices on HIV medicines for state AIDS drug programs www.statnews.com/pharmalot/20... via @statnews
👇
Gilead agrees not to raise prices on HIV medicines for state AIDS drug programs www.statnews.com/pharmalot/20... via @statnews
Gilead agrees not to raise prices on HIV medicines for state AIDS drug programs
After tense negotiations, Gilead Sciences has agreed not to boost prices next year for HIV medicines that are sold to state AIDS Drug Assistance Programs.
www.statnews.com
October 21, 2025 at 7:29 PM
Kudos to @GileadSciences for doing the right thing. Our statement is forthcoming...
👇
Gilead agrees not to raise prices on HIV medicines for state AIDS drug programs www.statnews.com/pharmalot/20... via @statnews
👇
Gilead agrees not to raise prices on HIV medicines for state AIDS drug programs www.statnews.com/pharmalot/20... via @statnews
Four Winn Awards scholars are redefining how communities engage in cancer research.
Funded by @gileadsciences, these projects show how community innovation drives #BetterScienceForAll.
winnawards.org/2025/10/adva...
Funded by @gileadsciences, these projects show how community innovation drives #BetterScienceForAll.
winnawards.org/2025/10/adva...
October 6, 2025 at 1:01 PM
Four Winn Awards scholars are redefining how communities engage in cancer research.
Funded by @gileadsciences, these projects show how community innovation drives #BetterScienceForAll.
winnawards.org/2025/10/adva...
Funded by @gileadsciences, these projects show how community innovation drives #BetterScienceForAll.
winnawards.org/2025/10/adva...
Thanks @pluslifemedia @gileadsciences & @glaad for inviting me to the HIV UNWRAPPED fashion show. It was really wonderful seeing the blend of science and fashion. Bravo to all involved 💙
September 25, 2025 at 11:19 PM
Thanks @pluslifemedia @gileadsciences & @glaad for inviting me to the HIV UNWRAPPED fashion show. It was really wonderful seeing the blend of science and fashion. Bravo to all involved 💙
🆕 US to support rollout of #lenacapavir in low- and middle-income countries – aiming to reach up to 2 million people through #PEPFAR & the #GlobalFund.
#GileadSciences will provide the drug at cost, without profit.
📰 Read more about this announcement in @npr.org!
#GileadSciences will provide the drug at cost, without profit.
📰 Read more about this announcement in @npr.org!
Why the medical community is thrilled by U.S. support for a 'breakthrough' HIV drug
Lenacapavir has the potential to end the HIV epidemic, researchers say. The Trump administration says backing this kind of effort will be a model for how it does global health work in the future.
www.npr.org
September 5, 2025 at 8:00 AM
🆕 US to support rollout of #lenacapavir in low- and middle-income countries – aiming to reach up to 2 million people through #PEPFAR & the #GlobalFund.
#GileadSciences will provide the drug at cost, without profit.
📰 Read more about this announcement in @npr.org!
#GileadSciences will provide the drug at cost, without profit.
📰 Read more about this announcement in @npr.org!
https://x.com/PEPFAR’s pre-market commitment to purchase https://x.com/GileadSciences new innovative drug lenacapavir champions American innovation and exemplifies https://x.com/SecRubio’s America First foreign assistance agenda 🇺🇸 https://www.state.
September 4, 2025 at 11:37 PM
https://x.com/PEPFAR’s pre-market commitment to purchase https://x.com/GileadSciences new innovative drug lenacapavir champions American innovation and exemplifies https://x.com/SecRubio’s America First foreign assistance agenda 🇺🇸 https://www.state.
#OPINIÓN | 🎙️ Reflexionamos con la Vicepresidenta de @GileadSciences España, María Río sobre su papel en la lucha para acabar con la pandemia del #VIH
https://www.consalud.es/opinion/podemos-acabar-con-la-pandemia-del-vih.html
https://www.consalud.es/opinion/podemos-acabar-con-la-pandemia-del-vih.html
September 4, 2025 at 5:31 PM
#OPINIÓN | 🎙️ Reflexionamos con la Vicepresidenta de @GileadSciences España, María Río sobre su papel en la lucha para acabar con la pandemia del #VIH
https://www.consalud.es/opinion/podemos-acabar-con-la-pandemia-del-vih.html
https://www.consalud.es/opinion/podemos-acabar-con-la-pandemia-del-vih.html
This week saw both #GileadSciences and #Amgen start to fulfil pledges to step up #capitalinvestments in new #US facilities.
pharmaphorum.com/news/gilead-...
pharmaphorum.com/news/gilead-...
Gilead, Amgen kick off facility investments in US
This week saw both Gilead Sciences and Amgen start to fulfil pledges to step up capital investments in new US facilities.
pharmaphorum.com
September 4, 2025 at 5:10 PM
This week saw both #GileadSciences and #Amgen start to fulfil pledges to step up #capitalinvestments in new #US facilities.
pharmaphorum.com/news/gilead-...
pharmaphorum.com/news/gilead-...
SFGiants 🤖
Today, marks the annual "Until There’s a Cure Night" at @OracleParkSF. During tonight's game, the #SFGiants will raise awareness for HIV/AIDS and pay tribute to those we've lost to this disease. Working together Until There's A Cure.
@GileadSciences | @UntilOrg
Today, marks the annual "Until There’s a Cure Night" at @OracleParkSF. During tonight's game, the #SFGiants will raise awareness for HIV/AIDS and pay tribute to those we've lost to this disease. Working together Until There's A Cure.
@GileadSciences | @UntilOrg
August 28, 2025 at 12:10 AM
SFGiants 🤖
Today, marks the annual "Until There’s a Cure Night" at @OracleParkSF. During tonight's game, the #SFGiants will raise awareness for HIV/AIDS and pay tribute to those we've lost to this disease. Working together Until There's A Cure.
@GileadSciences | @UntilOrg
Today, marks the annual "Until There’s a Cure Night" at @OracleParkSF. During tonight's game, the #SFGiants will raise awareness for HIV/AIDS and pay tribute to those we've lost to this disease. Working together Until There's A Cure.
@GileadSciences | @UntilOrg
💉 Evropská komise schválila registraci dvakrát ročně podávané injekce na prevenci viru #HIV od americké společnosti #GileadSciences.
Ke schválení se ve včerejších Událostech krátce vyjádřil také ředitel ÚOCHB Jan Konvalinka ► www.ceskatelevize.cz/porady/10971... ⤵️
#UOCHB #IOCB #IOCBPrague
Ke schválení se ve včerejších Událostech krátce vyjádřil také ředitel ÚOCHB Jan Konvalinka ► www.ceskatelevize.cz/porady/10971... ⤵️
#UOCHB #IOCB #IOCBPrague
August 27, 2025 at 5:52 PM
💉 Evropská komise schválila registraci dvakrát ročně podávané injekce na prevenci viru #HIV od americké společnosti #GileadSciences.
Ke schválení se ve včerejších Událostech krátce vyjádřil také ředitel ÚOCHB Jan Konvalinka ► www.ceskatelevize.cz/porady/10971... ⤵️
#UOCHB #IOCB #IOCBPrague
Ke schválení se ve včerejších Událostech krátce vyjádřil také ředitel ÚOCHB Jan Konvalinka ► www.ceskatelevize.cz/porady/10971... ⤵️
#UOCHB #IOCB #IOCBPrague
